Cargando…
Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor
When the human erythroleukemia cell line K562 is treated with OKT9, a monoclonal antibody against the transferrin receptor, effects on receptor dynamics and degradation ensue. The apparent half-life of the receptor is decreased by greater than 50% as a result of OKT9 treatment. The transferrin recep...
| Formato: | Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The Rockefeller University Press
1986
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2114135/ https://www.ncbi.nlm.nih.gov/pubmed/3005341 |